Advances in the Treatment and Prevention of Chemotherapy-Induced Ovarian Toxicity

Due to improvements in chemotherapeutic agents, cancer treatment efficacy and cancer patient survival rates have greatly improved, but unfortunately gonadal damage remains a major complication. Gonadotoxic chemotherapy, including alkylating agents during reproductive age, can lead to iatrogenic prem...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2020-10, Vol.21 (20), p.7792
Main Authors: Cho, Hyun-Woong, Lee, Sanghoon, Min, Kyung-Jin, Hong, Jin Hwa, Song, Jae Yun, Lee, Jae Kwan, Lee, Nak Woo, Kim, Tak
Format: Article
Language:English
Subjects:
Age
Alkylating agents
Alkylation
Antineoplastic Agents - adverse effects
Apoptosis
Artificial Organs
Birth rate
Breast cancer
Burnout
Cancer
Cancer therapies
Chemotherapy
Children & youth
Congenital diseases
Cryopreservation
Cryopreservation - methods
embryo cryopreservation
Embryo, Mammalian
Embryos
Estrogens
Female
Fertility
fertility preservation
Fertility Preservation - methods
Fertility Preservation - psychology
Gametocytes
gonadotoxicity
Humans
In vitro fertilization
In Vitro Oocyte Maturation Techniques - methods
Infertility
Kinases
Medical prognosis
Medical research
oocyte cryopreservation
oocyte in vitro maturation
Oocytes - physiology
ovarian tissue cryopreservation
Ovaries
Ovary - cytology
Ovary - drug effects
Ovary - physiology
Ovary - transplantation
Patients
Pregnancy
Primary Ovarian Insufficiency - prevention & control
Reproductive technologies
Review
Sperm donations
Stem cells
Toxicity
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Due to improvements in chemotherapeutic agents, cancer treatment efficacy and cancer patient survival rates have greatly improved, but unfortunately gonadal damage remains a major complication. Gonadotoxic chemotherapy, including alkylating agents during reproductive age, can lead to iatrogenic premature ovarian insufficiency (POI), and loss of fertility. In recent years, the demand for fertility preservation has increased dramatically among female cancer patients. Currently, embryo and oocyte cryopreservation are the only established options for fertility preservation in women. However, there is growing evidence for other experimental techniques including ovarian tissue cryopreservation, oocyte in vitro maturation, artificial ovaries, stem cell technologies, and ovarian suppression. To prevent fertility loss in women with cancer, individualized fertility preservation options including established and experimental techniques that take into consideration the patient's age, marital status, chemotherapy regimen, and the possibility of treatment delay should be provided. In addition, effective multidisciplinary oncofertility strategies that involve a highly skilled and experienced oncofertility team consisting of medical oncologists, gynecologists, reproductive biologists, surgical oncologists, patient care coordinators, and research scientists are necessary to provide cancer patients with high-quality care.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms21207792